

BJFIN reported a healthy Q1FY26, with a satisfactory performance across the lending (BAF) business; however, the general insurance business was a mixed bag. The life insurance segment delivered a strong margin. BAF reported a satisfactory quarter in terms of AUM growth, customer acquisition, operating efficiencies, and pre-provisioning profit; however, credit cost remained elevated. BAGIC saw an elevated CoR at 103.6%, on higher expense ratio, whereas claims ratio saw YoY improvement; BAGIC delivered a healthy PAT, aided by robust investment income. The life insurance business saw a strong VNB margin at 11.1% (+4.2ppt YoY), led by strategic initiatives and a higher focus on protection products driving a strong 39% VNB growth; however, APE declined ~13% YoY. To reflect the Q1 developments, we have tweaked our FY26-28E estimates which led to ~1-2% change in PAT over FY26-28E. We maintain ADD, with a revised Jun-26E TP of Rs2,200 (Rs2,100 earlier).

General insurance witnesses elevated CoR; Life delivers a strong margin

BJFIN's performance in Q1FY26 was reasonable, with the lending business (BAF) reporting a satisfactory performance driven by healthy AUM, PPOP, and PAT growth; however, asset quality saw a marginal decline. The general insurance business's performance was a mixed bag, with modest ~8% GWP growth and an elevated combined ratio at 103.6%, driven by higher expense ratio; claims ratio, though, saw improvement. PAT growth was healthy, driven by robust investment income on the back of higher capital gains realized. The Life insurance business delivered a strong VNB margin at 11.1% (+4.2ppt YoY), driven by a profit-focused strategy and a higher contribution of protection, leading to ~39% VNB growth; however, APE declined YoY.

Focus remains on a profitable growth strategy

The general insurance industry continues to grapple with challenges, with a slowdown in the motor segment, increased competition, and the impact of the 1/n regulation; BAGIC, however, has maintained its focus on growing profitably. While the company has prioritized underwriting lower-claims ratio segments, it has seen higher expense ratios, owing to increased distributor payouts to acquire high-quality business. With the implementation of the surrender regulations, BALIC has turned around its strategy to focus on profitability with significant changes in the product construct, which includes higher tenure products, rider attachments, and increasing the minimum ticket size across products. While the strategic shift has resulted in a decline in APE, increased VNB margins have resulted in strong VNB growth.

Minor tweaks in consolidated PAT; reiterate ADD

To reflect Q1 developments of improved margins for BAF, higher CoR, investment income for BAGIC, and improved VNB margins for BALIC, we tweak our FY26-28E consolidated PAT by ~1-2%. Given the strong franchise strength across the lending and insurance businesses, we reiterate ADD with a revised Jun-26E TP of Rs2,200 (from Rs2,100).

Target Price – 12M	Jun-26
Change in TP (%)	4.8
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	10.8

Stock Data	BJFIN IN
52-week High (Rs)	2,135
52-week Low (Rs)	1,523
Shares outstanding (mn)	1,597.8
Market-cap (Rs bn)	3,173
Market-cap (USD mn)	36,673
Net-debt, FY26E (Rs mn)	NA
ADTV-3M (mn shares)	2
ADTV-3M (Rs mn)	3,682.7
ADTV-3M (USD mn)	42.6
Free float (%)	34.2
Nifty-50	24,837.0
INR/USD	86.5

Shareholding, Mar-25

Promoters (%)	60.6
FPIs/MFs (%)	7.2/9.3

Price Performance

(%)	1M	3M	12M
Absolute	(1.3)	(2.9)	26.3
Rel. to Nifty	0.3	(6.0)	24.1

1-Year share price trend (Rs)



Bajaj Finserv: Financial Snapshot (Consolidated)

Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Net profits	81,478	88,723	118,675	145,797	181,973
AUM growth (%)	33.6	26.0	24.0	24.0	24.0
NII growth (%)	26.6	21.9	25.6	22.4	22.5
NIMs (%)	10.2	9.7	9.9	10.0	9.9
PPOP growth (%)	29.8	21.9	25.9	22.7	22.0
Adj. EPS (Rs)	51.2	55.6	74.4	91.4	114.0
Adj. EPS growth (%)	27.1	8.6	33.7	22.9	24.8
Adj. BV (INR)	378.4	453.6	527.0	617.3	730.3
Adj. BVPS growth (%)	29.9	19.9	16.2	17.1	18.3
RoA (%)	4.4	4.0	4.1	4.1	4.2
RoE (%)	22.0	19.3	19.9	20.8	21.6
P/E (x)	38.8	35.7	27.3	22.2	17.6
P/ABV (x)	5.2	4.4	3.8	3.2	2.7

Source: Company, Emkay Research; Note: AUM, NIMs, ROA, and ROE correspond to BAF

Avinash Singh

avinash.singh@emkayglobal.com
+91-22-66121327

Mahek Shah

mahek.shah@emkayglobal.com
+91-22-66121218

Kishan Rungta

kishan.rungta@emkayglobal.com
+91-22-66242490

This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions.com) use and downloaded at

Exhibit 1: Quarterly results summary

(Rs mn)	1QFY26	1QFY25	YoY change	4QFY25	QoQ change
BJFIN Consolidated - Ind AS					
Net worth	752,500	633,240	18.8%	723,950	3.9%
PAT	27,890	21,380	30.4%	24,170	15.4%
--o/w Bajaj Finance	24,160	20,090	20.3%	23,020	5.0%
--o/w General Insurance	4,450	3,650	21.9%	2,600	71.2%
--o/w Life Insurance	1,090	1,290	-15.5%	120	808.3%
--o/w Holdco and Consolidation	-1,810	-3,550	NM	-1,570	NM
Bajaj Finance - Ind AS					
AUM	4,414,500	3,541,920	25%	4,166,610	5.9%
PAT	47,650	39,120	21.8%	44,800	6.4%
GNPA (%)	1.03	0.86	17bps	0.96	7bps
NNPA (%)	0.50	0.38	12bps	0.44	6bps
Bajaj Allianz General - GAAP					
Gross written premium	52,020	48,056	8.2%	43,255	20.3%
Net earned Premium	22,289	22,315	-0.1%	22,700	-1.8%
PAT	6,600	5,760	14.6%	3,628	81.9%
Combined ratio (%)	103.6	103.7	-0.1ppts	104.8	-1.2ppts
Bajaj Allianz Life - GAAP					
APE	13,100	15,020	-12.8%	24,860	-47.3%
Individual WRP	12,550	12,940	-3.0%	23,280	-46.1%
Gross written premium	54,790	50,180	9.2%	92,370	-40.7%
VNB	1,450	1,040	39.4%	5,490	-73.6%
VNB Margin (%)	11.1	6.9	4.2ppts	22.1	-11ppts
PAT	1,710	970	76.3%	411	315.9%

Source: Company, Emkay Research

Exhibit 2: Estimates revision

(Rs mn)	FY26E			FY27E			FY28E		
	Old	Revised	Chg	Old	Revised	Chg	Old	Revised	Chg
Consolidated									
PAT	116,165	118,675	2%	146,555	145,797	-1%	180,368	181,973	1%
Net worth	838,523	841,032	0%	968,671	985,233	2%	1,158,302	1,165,610	1%
Bajaj Finance									
AUM	5,208,263	5,166,596	-1%	6,458,246	6,406,580	-1%	8,008,224	7,944,159	-1%
Net worth	1,139,991	1,143,300	0%	1,351,982	1,361,827	1%	1,620,797	1,634,363	1%
PPOP	367,521	372,155	1%	450,522	460,093	2%	557,132	562,081	1%
PAT	206,026	209,966	2%	252,371	260,151	3%	320,018	324,447	1%
Bajaj General									
GWP	237,961	237,961	0%	267,524	267,524	0%	301,901	301,901	0%
U/w Result	-656	-2,684	309%	194	-1,646	-949%	1,225	-311	-125%
Operating profit	19,767	19,184	-3%	22,997	21,410	-7%	26,458	25,181	-5%
PAT	19,608	19,539	0%	22,581	21,468	-5%	25,766	24,888	-3%
Combined ratio (%)	100.6	102.5	1.9ppts	99.6	101.0	1.4ppts	98.8	99.9	1.1ppts
RoE (%)	15.6	15.5	-0.1ppts	16.4	15.6	-0.8ppts	17.2	16.7	-0.5ppts
Bajaj Life									
APE	87,407	84,969	-3%	100,332	97,535	-3%	115,174	111,965	-3%
VNB	12,899	14,445	12%	15,007	17,556	17%	17,342	20,713	19%
VNB Margin (%)	14.8	17.0	2.2ppts	15.0	18.0	3.0ppts	15.1	18.5	3.4ppts
EV	264,167	265,012	0%	293,414	296,978	1%	325,917	333,259	2%
PAT	6,564	7,280	11%	7,475	7,370	-1%	7,475	7,370	-1%

Source: Company, Emkay Research


Exhibit 3: BJFIN – SOTP-based valuation

(Rs mn)	Parameter	FY27 Value	Implied Multiple	Valuation	BJFIN Stake	Value
Bajaj Finance	Net worth	1,361,827	4.6	6,208,500	51.3%	3,187,444
Bajaj Allianz General	PAT	21,468	28.1	602,779	74.0%	446,056
Bajaj Allianz Life	EV	296,978	1.5	446,529	74.0%	330,431
Holding company operations	PAT	990	15.0	14,850	100.0%	14,850
Bajaj Health	Revenue	12,934	5.0	64,670	100.0%	64,670
Bajaj Direct	Revenue	7,475	5.0	37,375	80.1%	29,949
Bajaj AMC	AUM	500,000	0.1	50,000	100.0%	50,000
BJFIN SoTP						4,123,400
Holdco discount on listed company		20%				-637,489
BJFIN Valuation						3,485,911
No of shares (mn)						1596.0
Fair Value per share (Rs)						2,184
Target price (Rs) - Jun-26E						2,200

Source: Company, Emkay Research


Story in charts

Exhibit 4: BJFIN's consolidated net worth grows 19% YoY




Source: Company, Emkay Research

Exhibit 5: BJFIN reports 30% YoY growth in consolidated PAT




Source: Company, Emkay Research

Exhibit 6: BAF reports robust 25% AUM growth in Q1FY26




Source: Company, Emkay Research

Exhibit 7: BAF's PAT grows 22% during Q1FY26




Source: Company, Emkay Research

Exhibit 8: BAGIC reports a 8% YoY growth in GWP




Source: Company, Emkay Research


Exhibit 9: Motor segment dominates the Q1FY26 product mix




Source: Company, Emkay Research

Exhibit 10: CoR remains elevated at 103.6% on the back of higher expense ratios


Source: Company, Emkay Research

Exhibit 11: BAGIC witnesses 15% growth in PAT, led by higher investment income


Source: Company, Emkay Research

Exhibit 12: BALIC witnesses a 13% decline in APE due to a change in strategy


Source: Company, Emkay Research

Exhibit 13: Share of Protection products increases YoY


Source: Company, Emkay Research

Exhibit 14: Led by favorable changes in the product mix, BALIC reports strong margin delivery


Source: Company, Emkay Research

Exhibit 15: Retail protection grows 43% YoY


Source: Company, Emkay Research

Exhibit 16: We expect BAGIC GWP growth to remain modest


Source: Company, Emkay Research

Exhibit 17: Gradual improvement in CoR over FY26-28E

Source: Company, Emkay Research

Exhibit 18: BALIC APE growth is expected to pick up in FY27E/28E

Source: Company, Emkay Research

Exhibit 19: We expect VNB margins to improve gradually over FY26-28E

Source: Company, Emkay Research

Earnings Conference Call Highlights

BAGIC

- The company endeavors to maintain the CoR close to ~100%. The management mentioned that despite market conditions, there has to be discipline in underwriting.
- Tender prices in the Crop segment were not favorable; hence, the company did not grow the crop segment during the quarter.
- The management stated that with its focus on profit, there will be higher acquisition costs for good quality business.
- Commissions have increased on account of business in the preferred segment. Further, the company has underwritten new business (compulsory 3Y/5Y business) in the Motor TP segment.
- CoR at 103.6% was elevated, driven by 1/n regulation change. Higher acquisition costs resulted in higher CoR on account of business in preferred segments. PAT grew 15%, attributable to better investment performance.

BALIC

- After the implementation of the new surrender regulations, the company has focused on profitability-driven growth. VNB growth was substantial in the recent quarter.
- Agency saw a 5Y CAGR of 25%. The company took a pause in the Agency channel during the quarter. The Agency channel has done a lot of heavy lifting, which has shown great results.
- The significant shift in Agency channel is owing to the focus on Term Plans.
- The management expects the Agency channel to witness slow growth in the next quarter as well, after which it is expected to pick up.
- The product mix has seen increased contribution from Protection.
- The product construct changed significantly which resulted in improved margins. Further, the company has also worked on cost-optimisation, which has resulted in higher margins.
- The rider attachment is healthy, and is currently 17% attachment across businesses.
- The company has increased the average premium to Rs30-35k, depending on the channels selling the Term Plans. Agency and Institutional channels are selling term products. There is ~9% increase in the ticket size.
- The management stated that the company is looking toward establishing a channel specifically focused on term plans.
- The management expects APE growth to revive during H2FY26.
- The management expects all the lines of Group Protection to pick up, with the uptake in credit disbursements.
- 30% of Agency customers are Term Plan customers. The management will maintain the pricing and quality of the protection book.

Exhibit 20: BJFIN – Financial Summary

(Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Profit before Tax	213,750	237,482	309,073	379,281	471,607
-- Bajaj Finance	193,096	2,796	282,593	350,136	436,672
--General Insurance	,550	24,452	26,051	28,624	33,184
--Life Insurance	5,716	5,601	7,428	7,5	8,752
--Holding company net of elimination	-5,611	-13,367	-7,000	-7,000	-7,000
Tax expense	57,797	61,906	80,688	98,691	122,096
Profit after tax	155,954	175,576	228,385	280,589	349,511
Minorities	74,476	86,853	109,710	134,792	167,539
Group Net income	81,478	88,723	118,675	145,797	181,973
Balance Sheet					
EQUITY AND LIABILITIES					
Share Capital	1,594	1,596	1,596	1,596	1,596
Shareholders' funds	603,286	723,953	841,032	985,233	1,165,610
Minority interest	434,472	560,389	596,513	704,675	839,494
Total Equity	1,037,759	1,284,342	1,437,545	1,689,908	2,005,104
Financial liabilities					
Borrowings	2,875,988	3,543,498	4,333,222	5,378,094	6,677,109
Policy liabilities	1,182,801	1,346,787	1,548,421	1,774,215	2,029,909
Linked liabilities	113,774	129,433	151,848	177,541	7,273
Discontinued fund liabilities					
Other long-term liabilities	113,125	147,738	174,828	210,940	255,217
Long-term provisions					
Total - financial liabilities	4,285,688	5,167,456	6,8317	7,540,791	9,169,508
Non-financial liabilities					
Other current liabilities	50,519	63,751	64,376	72,154	80,969
Provisions	5,330	6,767	8,007	9,661	11,689
Total - non-financial Liabilities	55,850	70,518	72,383	81,815	92,658
Total - Equity and Liabilities	5,379,296	6,522,316	7,718,246	9,312,514	11,267,270
ASSETS					
Total - Financial Assets	5,293,471	6,416,396	7,592,903	9,161,282	11,084,292
Total - Non-financial Assets	85,825	105,921	125,342	151,233	182,977
Total	5,379,296	6,522,316	7,718,246	9,312,514	11,267,270
Per share data (in Rs)					
Basic EPS	51.2	55.6	74.4	91.4	114.0
Diluted EPS	50.7	55.0	73.6	90.4	112.8
BVPS (LHS)	378.4	453.6	527.0	617.3	730.3
DPS	1.00	1.00	1.00	1.00	1.00
Key ratios					
Return on Equity (%)	15.3	13.4	15.2	16.0	16.9
PAT Growth (YoY %)	27.0	8.9	33.8	22.9	24.8

Source: Company, Emkay Research

Exhibit 21: BAGIC – Financial Summary

(Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Policyholders' account					
Gross Written Premium	206,300	215,829	237,961	267,524	301,901
Net Written Premium	95,684	90,606	109,831	125,890	142,793
Net earned premium	88,839	95,645	110,000	124,589	141,225
Investment income	16,709	18,591	20,972	22,160	24,595
Other income	535	896	896	896	896
Total revenue	106,083	115,132	131,868	147,646	166,716
Commission expense	6,439	3,761	8,915	9,487	10,113
Operating expenses	18,495	21,319	23,426	26,474	29,315
Claims incurred (Net)	65,559	71,340	80,343	90,275	102,108
Total expense	90,525	96,452	112,684	126,236	141,536
Operating profit	15,557	18,680	19,184	21,410	25,181
Shareholders' account					
Operating profit	15,557	18,680	19,184	21,410	25,181
Investment income	5,663	6,484	7,606	8,032	8,908
expenses	705	718	790	869	956
Profit before tax	20,550	24,452	26,051	28,624	33,184
Tax expense	5,046	6,129	6,513	7,156	8,296
Profit after tax	15,503	18,323	19,539	21,468	24,888
Balance Sheet	15.0%	18.2%	6.6%	9.9%	15.9%
Sources of Funds					
Shareholders' Funds	108,413	120,122	131,845	142,580	155,023
Fair value gains	6,323	4,862	5,349	5,884	6,472
Total	114,736	124,985	137,194	148,463	161,495
Application of Funds					
Investments	301,680	317,295	361,297	399,481	450,062
Other non-current assets	5,210	5,174	5,432	5,703	5,987
Current Assets:					
Cash and Bank Balances	10,299	13,860	15,246	16,009	16,809
Other current assets	50,982	73,507	80,857	88,943	97,837
Current liabilities					
Claim reserves	201,947	238,369	293,910	322,152	365,168
Provisions	51,488	46,482	57,313	62,820	71,208
Net Current Assets	-192,154	-197,484	-255,119	-280,021	-321,730
Total	114,736	124,985	137,194	148,463	161,495
Key Ratio (%)					
Retention ratio	46.4	42.0	46.2	47.1	47.3
NEP/NWP	92.8	105.6	100.2	99.0	98.9
Claims ratio	73.8	74.6	73.0	72.5	72.3
Commission ratio	6.7	4.2	8.1	7.5	7.1
Opex ratio	19.3	23.5	21.3	21.0	20.5
Combined ratio	99.9	102.3	102.5	101.0	99.9
Reported combined ratio	99.9	102.3	102.5	101.0	99.9
GWP growth	33.2	4.6	10.3	12.4	12.9
Tax rate	24.6	25.1	25.0	25.0	25.0
Return on equity	15.2	16.0	15.5	15.6	16.7

Source: Company, Emkay Research

Exhibit 22: BALIC – Financial Summary

(Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Policyholders' account					
Net earned premium	226,633	266,897	308,577	358,038	413,916
Investment income	146,296	90,655	116,471	133,505	155,970
Other income	885	1,140	0	0	0
Total revenue	373,813	358,693	425,048	491,543	569,886
Commission expense	20,593	31,068	35,919	41,677	48,181
Operating expenses	38,303	42,485	47,576	53,412	59,678
Benefits cost	124,500	131,256	143,131	167,919	196,332
Total expense	376,054	362,137	425,711	491,238	568,292
Surplus/Deficit	-2,241	-3,445	-663	305	1,594
Shareholders' account					
Transfer from policyholders' account	10,352	8,665	12,706	15,060	17,873
Investment income	8,871	10,086	9,476	8,664	8,678
expenses	13,523	13,219	14,754	16,204	17,799
Profit before tax	5,716	5,601	7,428	7,520	8,752
Tax expense	90	520	149	150	175
Profit after tax	5,626	5,081	7,280	7,370	8,577
Embedded Value Account					
Embedded Value	217,260	238,050	265,012	296,978	333,259
--o/w Adjusted Net Worth	128,210	135,570	141,882	142,085	142,322
--o/w Value-in-Force	89,050	102,480	123,130	154,893	190,937
Annualised Premium equivalent (APe)	72,740	79,410	84,969	97,535	111,965
New Business value	10,610	11,520	14,445	17,556	20,713
New Business Margin (%)	14.6	14.5	17.0	18.0	18.5
EV Operating Profit	26,950	27,610	33,088	38,179	43,675
Operating RoEV (%)	14.5	12.7	13.9	14.4	14.7

Source: Company, Emkay Research

Bajaj Finserv: Consolidated Financials and Valuations

Profit & Loss					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Interest Income	537,932	674,491	831,823	1,017,209	1,252,406
Interest Expense	183,995	243,097	289,984	353,943	439,627
Net interest income	353,937	431,394	541,839	663,266	812,779
NII growth (%)	26.6	21.9	25.6	22.4	22.5
Non interest income	565,898	663,731	665,717	776,602	909,893
Total income	919,835	1,095,124	1,207,556	1,439,868	1,722,671
Operating expenses	659,830	778,346	808,599	950,252	1,125,207
PPOP	260,086	316,958	399,057	489,716	597,564
PPOP growth (%)	29.8	21.9	25.9	22.7	22.0
Provisions & contingencies	46,336	79,476	89,784	110,235	125,757
PBT	213,750	237,482	309,273	379,481	471,807
Extraordinary items	-	-	-	-	-
Tax expense	57,797	61,906	80,688	98,691	122,096
Minority interest	74,476	86,853	109,710	134,792	167,539
Income from JV/Associates	81	180	100	100	100
Reported PAT	81,478	88,723	118,675	145,797	181,973
PAT growth (%)	27.0	8.9	33.8	22.9	24.8
Adjusted PAT	81,478	88,723	118,675	145,797	181,973
Diluted EPS (Rs)	51.2	55.6	74.4	91.4	114.0
Diluted EPS growth (%)	27.1	8.6	33.7	22.9	24.8
DPS (Rs)	-	-	-	-	-
Dividend payout (%)	-	-	-	-	-
Effective tax rate (%)	27.0	26.1	26.1	26.0	25.9
Net interest margins (%)	10.2	9.7	9.9	10.0	9.9
Cost-income ratio (%)	34.0	33.2	33.4	33.5	34.4
PAT/PPOP (%)	60.4	55.9	56.4	56.5	57.7
Shares outstanding (mn)	1,594.1	1,596.0	1,596.0	1,596.0	1,596.0

Source: Company, Emkay Research Note: NIM, Cost to Income and PAT/PPOP for BAF

Asset quality and other metrics					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Asset quality					
GNPL - Stage 3	28,160	39,650	42,481	50,034	62,042
NNPL - Stage 3	12,100	18,350	20,100	24,104	30,455
GNPL ratio - Stage 3 (%)	0.8	1.0	0.8	0.8	0.8
NNPL ratio - Stage 3 (%)	0.4	0.4	0.4	0.4	0.4
ECL coverage - Stage 3 (%)	57.0	53.7	52.7	51.8	50.9
ECL coverage - 1 & 2 (%)	1.0	1.2	1.2	1.1	0.8
Gross slippage - Stage 3	0	0	0	0	0
Gross slippage ratio (%)	-	-	-	-	-
Write-off ratio (%)	1.7	1.8	1.9	1.9	2.0
Total credit costs (%)	1.6	2.1	1.9	1.9	1.8
NNPA to networth (%)	1.6	1.9	1.8	1.8	1.9
Capital adequacy					
Total CAR (%)	22.5	21.9	21.3	20.7	20.1
Tier-1 (%)	21.5	21.1	20.5	19.9	19.3
Miscellaneous					
Total income growth (%)	31.6	19.1	10.3	19.2	19.6
Opex growth (%)	32.4	18.0	3.9	17.5	18.4
PPOP margin (%)	8.3	8.0	8.0	8.0	7.8
Credit costs-to-PPOP (%)	19.3	26.5	24.1	24.0	22.4
Loan-to-Assets (%)	86.8	87.5	88.1	88.7	89.5
Yield on loans (%)	16.7	16.4	16.2	16.1	16.0
Cost of funds (%)	7.4	7.6	7.3	7.2	7.2
Spread (%)	9.3	8.7	8.9	8.8	8.8

Source: Company, Emkay Research Note: Total Income growth and Opex growth for BJFIN

Balance Sheet					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	1,594	1,596	1,596	1,596	1,596
Reserves & surplus	1,036,164	1,282,746	1,435,949	1,688,312	2,003,508
Net worth	1,037,759	1,284,342	1,437,545	1,689,908	2,005,104
Borrowings	2,875,988	3,543,498	4,333,222	5,378,094	6,677,109
Other liabilities & prov.	1,465,550	1,694,475	1,947,479	2,244,512	2,585,057
Total liabilities & equity	5,379,296	6,522,316	7,718,246	9,312,514	11,267,270
Net loans	3,267,422	4,084,908	4,996,105	6,194,272	7,704,162
Investments	1,680,018	1,897,295	2,175,403	2,515,362	2,912,634
Cash, other balances	123,867	157,368	103,047	85,547	46,480
Interest earning assets	5,071,307	6,139,570	7,274,554	8,795,180	10,663,276
Fixed assets	49,861	58,083	62,839	69,123	76,035
Other assets	258,129	324,663	380,852	448,211	527,959
Total assets	5,379,296	6,522,316	7,718,246	9,312,514	11,267,270
BVPS (Rs)	378.4	453.6	527.0	617.3	730.3
Adj. BVPS (INR)	378.4	453.6	527.0	617.3	730.3
Gross loans	3,313,344	4,148,270	5,068,756	6,280,569	7,787,906
Total AUM	3,306,150	4,166,610	5,166,596	6,406,580	7,944,159
On balance sheet	3,313,344	4,148,270	5,068,756	6,280,569	7,787,906
Off balance sheet	(7,193)	18,340	97,840	126,010	156,253
Disbursements	-	-	-	-	-
Disbursements growth (%)	0	0	0	0	0
Loan growth (%)	34.6	25.0	22.3	24.0	24.4
AUM growth (%)	33.6	26.0	24.0	24.0	24.0
Borrowings growth (%)	36.0	23.2	22.3	24.1	24.2
Book value growth (%)	29.9	19.9	16.2	17.1	18.3

Source: Company, Emkay Research Note: Gross Loans and AUM for BAF

Valuations and key Ratios					
Y/E March	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	38.8	35.7	27.3	22.2	17.6
P/B (x)	5.2	4.4	3.8	3.2	2.7
P/ABV (x)	5.2	4.4	3.8	3.2	2.7
P/PPOP (x)	12.2	10.0	7.9	6.5	5.3
Dividend yield (%)	0	0	0	0	0
Dupont-RoE split (%)					
NII/avg AUM	10.2	9.7	9.9	10.0	9.9
Other income	2.3	2.3	2.0	2.0	2.0
Securitization income	-	-	-	-	-
Opex	2.1	2.0	2.0	2.0	2.1
Employee expense	2.2	2.0	2.0	2.0	2.0
PPOP	8.3	8.0	8.0	8.0	7.8
Provisions	1.6	2.1	1.9	1.9	1.8
Tax expense	1.7	1.4	1.6	1.6	1.6
RoAUM (%)	5.0	4.5	4.5	4.5	4.5
Leverage ratio (x)	4.4	4.3	4.4	4.6	4.8
RoE (%)	22.0	19.3	19.9	20.8	21.6

Quarterly data					
Rs mn, Y/E Mar	Q1FY25	Q2FY25	Q3FY25E	Q4FY25	Q1FY26
BAGIC GWP	48,056	58,710	66,257	43,255	52,020
BAGIC PAT	5,760	4,940	2,900	3,628	6,600
BAGIC Combined Ratio (%)	103.7	101.4	101.1	104.8	103.6
BALIC APE	15,020	22,680	16,850	24,860	13,100
BALIC VNB Margin (%)	6.9	10.8	15.1	22.1	11.1


Source: Company, Emkay Research Note: Dupont-RoE split for BAF

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
02-May-25	1,958	2,100	Add	Avinash Singh
03-Apr-25	1,920	2,100	Add	Avinash Singh
18-Mar-25	1,845	2,000	Buy	Avinash Singh
01-Feb-25	1,754	2,000	Buy	Avinash Singh
28-Oct-24	1,730	2,050	Buy	Avinash Singh
23-Oct-24	1,740	2,150	Buy	Avinash Singh
13-Sep-24	1,894	2,150	Buy	Avinash Singh

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of July 27, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of July 27, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the July 27, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.